다른 서비스와 비교했을 때 CNSP 의 PB 비율은 어느 정도인가요?

CNSP은 Price-To-Book 비율(1.7x)을 기준으로 볼 때 동종 업체의 평균(1x)과 비교했을 때 비쌉니다.

CNSP 의 PB 비율은 US Pharmaceuticals 업계의 다른 회사와 어떻게 비교됩니까?

CNSP 은 Price-To-Book 1.7 US Pharmaceuticals 업계 평균( 1.7 x).

CNSP 의 PB 비율과 공정 PB 비율은 어떻게 되나요? 회사의 예상 수익 성장률, 이익 마진 및 기타 위험 요소를 고려한 예상 PB 비율입니다.

평가 분석을 위한 CNSP 의 Price-To-Book 공정 비율을 계산하기에는 데이터가 부족합니다.

미래 현금 흐름을 볼 때 CNSP 의 공정 가격은 얼마인가요? 이 추정에는 할인된 현금흐름 모델을 사용합니다.

평가 분석을 위해 CNSP 의 공정 가치를 계산하기에는 데이터가 부족합니다.

애널리스트의 12개월 전망은 무엇이며 컨센서스 목표가에 대한 통계적 신뢰도가 있나요?

가격 예측을 표시하기에는 데이터가 부족합니다.

CNS Pharmaceuticals (Nasdaq:CNSP) - 주가, 뉴스 및 분석

CNSP 주식 개요

임상 제약 회사인 CNS 제약은 뇌 및 중추신경계 종양 치료를 위한 항암제 후보 물질을 개발하는 회사입니다. 자세한 내용

CNSP 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

의미 있는 시가총액이 없습니다. ( $6M )

수익이 1백만 달러 미만인 경우 ( $0 )

최근 3개월간 주가 변동성

+ 1 더 많은 위험

CNS Pharmaceuticals, Inc. 경쟁사

Evoke Pharma

NasdaqCM:EVOK

US$6.5m

Adial Pharmaceuticals

NasdaqCM:ADIL

US$6.4m

Polydex Pharmaceuticals

OTCPK:POLX.F

US$6.8m

Mystic Holdings

OTCPK:MSTH

US$6.5m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 CNS Pharmaceuticals
과거 주가
현재 주가	US$0.12
52주 최고치	US$114.50
52주 최저치	US$0.096
베타	1.05
11개월 변경	-20.41%
3개월 변경 사항	-21.50%
1년 변경 사항	-99.89%
33년 변화	-99.99%
5년 변화	-100.00%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

CNS Pharmaceuticals reports Q2 results

Aug 15

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

Dec 04

CNS Pharmaceuticals sinks after pricing equity offering of $10M

Dec 23

주주 수익률

	CNSP	US Pharmaceuticals	US 마켓
7D	-6.6%	3.4%	1.6%
1Y	-99.9%	14.2%	32.3%

수익률 대 산업: CNSP 지난 1년 동안 14.2 %를 반환한 US Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: CNSP 지난 1년 동안 32.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is CNSP's price volatile compared to industry and market?
CNSP volatility
CNSP Average Weekly Movement	13.4%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

안정적인 주가: CNSP 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: CNSP 의 주간 변동성은 지난 1년 동안 21% 에서 13% 로 감소했지만 여전히 US 주식의 75%보다 높습니다.

회사 소개

설립	직원	CEO	웹사이트
2017	4	John Climaco	www.cnspharma.com

임상 제약 회사인 씨앤에스 파마슈티컬스는 뇌 및 중추신경계 종양 치료를 위한 항암제 후보 물질을 개발하는 회사입니다. 이 회사의 주요 약물 후보는 다형성 교모세포종 치료에 사용되는 임상 1상 시험을 완료한 베루비신입니다. CNS 파마슈티컬스는 휴스턴 파마슈티컬스, 텍사스대학교 엠디앤더슨 암센터와 라이선스 계약을 체결했으며 리아타 파마슈티컬스와 협력 및 자산 매입 계약을 체결했습니다.

CNS Pharmaceuticals, Inc. 기본 사항 요약

CNS Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
CNSP 기본 통계
시가총액	US$5.77m
수익(TTM)	-US$17.06m
수익(TTM)	n/a

0.0x

P/S 비율

-0.3x

P/E 비율

CNSP 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
CNSP 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$17.06m
수익	-US$17.06m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.34
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0.9%

CNSP 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

CNSP 주식 개요

위험 분석

CNS Pharmaceuticals, Inc. 경쟁사

NasdaqCM:EVOK

US$6.5m

NasdaqCM:ADIL

US$6.4m

OTCPK:POLX.F

US$6.8m

OTCPK:MSTH

US$6.5m

가격 내역 및 성능

최근 뉴스 및 업데이트

CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million.

The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024

Recent updates

CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million.

The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. announced a financing transaction

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3725 million.

New major risk - Share price stability

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq

CNS Pharmaceuticals Provides Non-Compliance Update

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

New major risk - Negative shareholders equity

CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland

Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (Gbm)

CNS Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement Pursuant to Nasdaq’s Listing Rule 5550(b)(1)

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Investigator-Initiated Phase 1B/2 Trial to Be Conducted At the Pomeranian Medical University in Poland

Cns Pharmaceuticals, Inc. Appoints Faith Charles as Independent Member and as Chairperson of the Board of Directors

CNS Pharmaceuticals, Inc Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Insufficient new directors

CNS Pharmaceuticals, Inc. Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Provides A Clinical Update of Its Anti-Cancer Drug Candidates Currently in Development for the Treatment of Primary and Metastatic Brain and CNS Cancer

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2022

CNS Pharmaceuticals Inc. Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Price target increased to US$10.00

Insufficient new directors

CNS Pharmaceuticals, Inc. Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals, Inc. announced that it expects to receive $11.500001 million in funding

Insufficient new directors

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

CNS Pharmaceuticals, Inc. Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

FDA Grants Fast Track Designation to CNS Pharmaceuticals, Inc. for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals Berubicin Trial is on Schedule to Commence in March 2021

WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announces Berubicin Supply Agreement for the Upcoming Clinical Trials

WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

New 90-day high: US$3.50

CNS Pharmaceuticals Announces It Has Been Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application

CNS Pharmaceuticals sinks after pricing equity offering of $10M

CNS Pharmaceuticals, Inc. Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

New 90-day high: US$2.89

주주 수익률

가격 변동성

회사 소개

CNS Pharmaceuticals, Inc. 기본 사항 요약

0.0x